Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Summary

The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.

Timeline

Start

2021-06-22

Primary completion

2024-02-07

Completion

2024-02-15

Publications

• Wu SS, Colevas AD, Martinez Ramirez L, Megwalu UC, Chen MM, Atwell A, Divi V. Cost of Neoadjuvant Immunotherapy vs Up-Front Surgery in Cutaneous Squamous Cell Carcinoma: A Post Hoc Analysis of a Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025 May 1;151(5):495-502. doi: 10.1001/jamaoto.2025.0001.

Drugs

Indications